摘要
目的:以参与城镇职工基本医疗保险的基因1b型慢性丙型肝炎患者为目标人群,对直接抗病毒药物纳入医保目录后的基金支出进行预算影响分析。方法:通过对目标人群、不同产品市场份额和医保支付金额的设定与计算,以2018年为基线年,分析今后5年内DAAs纳入医保目录对医保基金支出的影响。结果:DAAs进入医保目录后,医保基金支出增加,5年累计增幅19.63%;治愈总人数增加,5年累计增幅92.30%;DAAs医保支付标准的变化对基础结果的影响较大。结论:DAAs进入医保目录后,由于接受治疗的患者人数增加,短期内医保基金支出可能增加,随着患者存量减少,医保基金支出也将相应下降。
Objective To analyze the budgetary impact of taking direct antiviral drugs(DAAs)into the medical insurance catalogue among patients with type 1b chronic hepatitis C who participated in urban workers'basic medical insurance.Methods Through the setting and calculation of the target population,market share of different products,and the amount of medical insurance payment,the impact of taking DAAs into the medical insurance catalogue on the expenditure of medical insurance funds in the next five years will be analyzed with 2018 as the baseline year.Results After the DAAs entered the medical insurance catalogue,the expenditure of the medical insurance fund increased,and the cumulative increase in the five years was 19.63%;the total number of cured patients increased,and the cumulative increase in the five years was 92.30%;the change in the DAAs medical insurance payment standard had a greater impact on the basic results.Conclusion After the DAAs entered the medical insurance catalogue,due to the increases in the number of patients receiving treatment,the expenditure on medical insurance funds may increase in the short term.As the stock of patients decreases,the expenditure on medical insurance funds will also decrease accordingly.
作者
陈平钰
李洪超
马爱霞
CHEN Ping-yu;LI Hong-chao;MA Ai-xia(International Pharmaceutical Business School of China Pharmaceutical University,Nanjing Jiangsu 211198,China)
基金
2018年江苏省研究生培养创新工程项目(KYCX18_0831)
关键词
直接抗病毒药物
慢性丙型肝炎
预算影响分析
医保目录
direct antiviral drug
chronic hepatitis C
budgetary impact analysis
medical insurance catalog
